# US 2016/0354514 A1 · Multiphasic bone graft substitute material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354514 A1
- Document ID: US20160354514A1
- Status: Published application
- Kind: A1
- Application number: 15/238,130
- Filed: 2016-08-16
- Published: 2016-12-08
- Earliest claimed: 2013-12-13
- Assignees: Agnovos Healthcare, LLC
- Applicants: Agnovos Healthcare, LLC
- Inventors: Jon P. Moseley; Jamie MacDougall; Katie Harrigan
- Web page: https://patentgrep.com/patent/US20160354514A1

## CPC

- A61L 27/12: Phosphorus-containing materials, e.g. apatite
- A61L 24/0015: {Medicaments; Biocides}
- A61L 24/02: containing inorganic materials
- A61L 27/025: {Other specific inorganic materials not covered by A61L27/04 - A61L27/12}
- A61L 27/3608: {Bone, e.g. demineralised bone matrix [DBM], bone powder}
- A61L 27/3641: {characterised by the site of application in the body (materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60)}
- A61L 27/3821: {Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells}
- A61L 27/3847: {Bones}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- C04B 28/14: containing calcium sulfate cements {(gypsum-paper plates E04C)}
- C04B 28/34: containing cold phosphate binders
- A61L 2300/10: containing or releasing inorganic materials
- A61L 2300/102: Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L 2300/112: Phosphorus-containing compounds, e.g. phosphates, phosphonates
- A61L 2300/414: Growth factors
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- C04B 2111/00836: {for medical or dental applications}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C04B: LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE {(roofing granules E04D7/005)}; CERAMICS (devitrified glass-ceramics C03C10/00); REFRACTORIES; TREATMENT OF NATURAL STONE

## Abstract

The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; iii) a non-porous β-tricalcium phosphate powder; and iv) a porous β-tricalcium phosphate powder. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

## Claims

### Claim 1

A particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, comprising:
i) a calcium sulfate hemihydrate powder, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 50 weight percent based on the total weight of the particulate composition; and
ii) porous β-tricalcium phosphate particulates in the form of either a powder, granules, or a mixture of powder and granules.

### Claim 2 (depends on 1)

The particulate composition of claim 1, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition.

### Claim 3 (depends on 1)

The particulate composition of claim 1, wherein the calcium sulfate hemihydrate powder has a bimodal particle distribution.

### Claim 4 (depends on 3)

The particulate composition of claim 3, wherein the calcium sulfate hemihydrate powder has a median particle size of about 5 to about 20 microns.

### Claim 5 (depends on 1)

The particulate composition of claim 1, wherein the porous β-tricalcium phosphate particulates exhibits a bimodal particle size distribution.

### Claim 6 (depends on 5)

The particulate composition of claim 5, wherein the porous β-tricalcium phosphate particulates comprises less than 50% by weight of particles having a particle size up to about 63 microns and greater than 50% by weight of particles having a particle size greater than about 63 microns.

### Claim 7 (depends on 5)

The particulate composition of claim 5, wherein the porous β-tricalcium phosphate particulates comprises about 25% by weight of particles having a particle size up to about 63 microns and about 75% by weight of particles having a particle size greater than about 63 microns.

### Claim 8 (depends on 1)

The particulate composition of claim 1, wherein the calcium sulfate hemihydrate is α-calcium sulfate hemihydrate.

### Claim 9 (depends on 1)

The particulate composition of claim 1, wherein the calcium sulfate hemihydrate powder has a bimodal particle distribution comprising about 30 to about 60 volume percent of particles having a mode of about 1.0 to about 3.0 microns and about 40 to about 70 volume percent of particles having a mode of about 20 to about 30 microns, based on the total volume of the calcium sulfate hemihydrate powder.

### Claim 10 (depends on 1)

The particulate composition of claim 1, wherein the porous β-tricalcium phosphate particulates is present at a concentration of between about 5 and about 15 weight percent based on the total weight of the particulate composition.

### Claim 11 (depends on 1)

The particulate composition of claim 1, further comprising an accelerant adapted for accelerating the conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate.

### Claim 12 (depends on 11)

The particulate composition of claim 11, wherein the accelerant is selected from the group consisting of calcium sulfate dihydrate particles, potassium sulfate particles, and sodium sulfate particles, wherein the accelerant is optionally coated with sucrose.

### Claim 13 (depends on 11)

The particulate composition of claim 11, wherein the accelerant is present at a concentration of up to about 1 weight percent based on the total weight of the particulate composition.

### Claim 14 (depends on 1)

The particulate composition of claim 1, wherein the porous β-tricalcium phosphate particulates have a pore size in the range from about 100 microns to about 400 microns.

### Claim 15 (depends on 1)

The particulate composition of claim 1, wherein the porous β-tricalcium phosphate particulates is characterized by an interconnected, multidirectional porosity.

### Claim 16 (depends on 1)

The particulate composition of claim 1, wherein the porous β-tricalcium phosphate particulates has a total porosity of at least about 50%.

### Claim 17 (depends on 1)

The particulate composition of claim 1, further comprising a biologically active agent.

### Claim 18 (depends on 17)

The particulate composition of claim 17, wherein the biologically active agent is selected from the group consisting of cancellous bone chips, growth factors, antibiotics, pesticides, chemotherapeutic agents, antivirals, analgesics, and anti-inflammatory agents.

### Claim 19 (depends on 17)

The particulate composition of claim 17, wherein the biologically active agent is bone marrow aspirate.

### Claim 20 (depends on 17)

The particulate composition of claim 17, wherein the biologically active agent is a growth factor selected from the group consisting of fibroblast growth factors, platelet-derived growth factors, bone morphogenic proteins, osteogenic proteins, transforming growth factors, LIM mineralization proteins, osteoid-inducing factors, angiogenins, endothelins; growth differentiation factors, ADMP-1, endothelins, hepatocyte growth factor and keratinocyte growth factor, heparin-binding growth factors, hedgehog proteins, interleukins, colony-stimulating factors, epithelial growth factors, insulin-like growth factors, cytokines, osteopontin, and osteonectin.

### Claim 21

A particulate composition, comprising:
i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition; and
ii) porous β-tricalcium phosphate particulates, in an amount of up to about 15 weight percent based on the total weight of the particulate composition, wherein the porous β-tricalcium phosphate particulates comprises less than 50% by weight of particles having a particle size up to about 63 microns and greater than 50% by weight of particles having a particle size greater than about 63 microns.

### Claim 22 (depends on 21)

The particulate composition of claim 21, wherein the porous β-tricalcium phosphate particulates have a pore size in the range from about 100 microns to about 400 microns.

### Claim 23 (depends on 21)

The particulate composition of claim 21, wherein the porous β-tricalcium phosphate particulates is characterized by an interconnected, multidirectional porosity.

### Claim 24 (depends on 21)

The particulate composition of claim 21, wherein the porous β-tricalcium phosphate particulates has a total porosity of at least about 50%.
